Core Viewpoint - Meiz Health (02415) expects to record a profit attributable to shareholders of no less than RMB 10 million for the six months ending June 30, 2025, compared to a profit of RMB 200,000 for the six months ending June 30, 2024, indicating a significant increase in profitability driven by various factors [1] Group 1: Profit Expectations - The company anticipates a substantial increase in profit, projecting at least RMB 10 million for the upcoming six-month period [1] - In contrast, the profit for the previous comparable period was only RMB 200,000, highlighting a significant year-on-year improvement [1] Group 2: Factors Contributing to Profit Increase - The recovery of the pharmaceutical industry and the accelerated transformation of domestic pharmaceutical companies towards evidence-driven marketing models are driving demand for precise omnichannel marketing solutions [1] - The application of artificial intelligence is enhancing production efficiency across various business segments of the company [1] - The active implementation of environmental, social, and governance (ESG) principles is leading to more effective control of operational costs [1]